Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Surufatinib + Toripalimab-tpzi |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | lung non-small cell carcinoma | predicted - sensitive | Surufatinib + Toripalimab-tpzi | Phase II | Actionable | In a Phase II trial, Surufatinib (HMPL-012) plus Loqtorz (toripalimab-tpzi) treatment resulted in an objective response rate of 57.1%, a disease control rate of 100%, a median duration of response of 8.31 months, a median progression-free survival of 9.63 months, a median overall survival (OS) that was not reached, and a 12-month OS rate of 64% in patients with CD274 (PD-L1)-positive (TPS>=1%) non-small cell lung cancer (Cancer Res (2023) 83 (8_Supplement): CT225; NCT04169672). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
Abstract CT225: Surufatinib plus toripalimab for first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 positive expression: A multicenter, single-arm phase 2 study | Full reference... |